Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915261 | 0.94 | ALDH1A1 (0.59) | ALDH1A1HDAC8HDAC1HDAC6CYP1A2 | |
| SCHEMBL655826 | 0.86 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL728203 | 0.86 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2ALOX5GAA | |
| Hydrochloric Acid SCHEMBL2553196 | 0.85 | ALDH1A1 (0.51) | ALDH1A1CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL570110 | 0.82 | GAA (0.61) | ALDH1A1MAPTHSD17B10LMNAGAA | |
| SCHEMBL12144981 | 0.82 | ALOX5 (0.49) | ALDH1A1HDAC8HDAC1HDAC6ALOX5 | |
| SCHEMBL730002 | 0.82 | HTR2A (0.51) | HDAC8HDAC1HDAC6MAPTSMN1; SMN2 | |
| SCHEMBL7601782 | 0.81 | ALOX5 (0.55) | ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL2875409 | 0.81 | ALDH1A1 (0.57) | ALDH1A1HDAC8HDAC1HDAC6CYP1A2 | |
| Hydrochloric Acid SCHEMBL15488205 | 0.81 | GAA (0.59) | ALDH1A1MAPTHSD17B10LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2018-03-08 | — | — | US | claimed |
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2811993-A2 | METHODS OF TREATING FIBROSIS | Nogra Pharma Limited (IE) | 2014-12-17 | — | — | EP | claimed |
| WO-2013117744-A9 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2013-10-03 | — | — | WO | claimed |
| WO-2013117744-A2 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2013-08-15 | — | — | WO | claimed |
| CN-101243043-B | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INT LTD | 2013-03-20 | — | — | CN | claimed |
| EP-1910275-B1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | NOGRA PHARMA LTD (IE) | 2013-02-13 | — | — | EP | claimed |
| EP-2131829-B1 | PPAR-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants | GIULIANI INT LTD (IE) | 2012-04-18 | — | — | EP | claimed |
| US-8138357-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-03-20 | — | — | US | claimed |
| CN-102264361-A | Method for preventing or reducing carcinogenesis or oxidative stress | — | 2011-11-30 | — | — | CN | claimed |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| CN-101969943-A | Compounds for the selective treatment of the intestinal immunoinflammatory component of celiac disease | GIULIANI INT LTD | 2011-02-09 | — | — | CN | claimed |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | NOGRA PHARMA LIMITED (IE) | 2010-12-02 | — | — | US | claimed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | claimed |
| CN-101243043-A | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INT LTD (IE) | 2008-08-13 | — | — | CN | claimed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| WO-1998005627-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND HIGHLY STABLE COMPLEXES | PROLINX, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1998005629-A1 | BORONIC COMPOUND COMPLEXING REAGENTS AND COMPLEXES | PROLINX, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | ALDH1A1 664/4885HDAC8 815/4885HDAC1 609/4885 |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | ALDH1A1 2287/4885HDAC8 2263/4885HDAC1 1645/4885 |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | SI, FABP2, NFKBIA | ALDH1A1 2703/4885HDAC8 1704/4885HDAC1 1339/4885 |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | ALDH1A1 664/4885HDAC8 815/4885HDAC1 609/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | ALDH1A1 664/4885HDAC8 815/4885HDAC1 609/4885 |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | ALDH1A1 103/4885HDAC8 2979/4885HDAC1 1420/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | ALDH1A1 983/4885HDAC8 2540/4885HDAC1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.